Sorafenib, targeting VEGFR1-3, PDGFR-β, FLT-3, c-KIT, RAF kinases, for hepatocellular and renal cell carcinomas and thyroid cancer. Here, FLT3 is linked to hereditary clear cell renal cell carcinoma.